SUMMARY We studied the effect of cisapride on oesophageal motor function and postprandial gastro-oesophageal reflux in a randomised, double blind, placebo controlled crossover study. In 16 patients with symptomatic gastro-oesophageal reflux, cisapride 10 mg orally and placebo were studied on separate days according to identical protocols. Cisapride and placebo were given 30 minutes before a standard meal. Each study day was preceded by corresponding three day oral loading of cisapride (10 mg tds) or placebo. Lower oesophageal sphincter pressure, oesophageal body motility and oesophageal pH were monitored for 30 minutes before and three hours after the meal. Plasma cisapride concentrations were measured before and after dosing on both study days. With cisapride treatment, the plasma cisapride levels ranged from 48.1 (5.0) to 75.9 (6.9) ng/ml. Plasma levels were undetectable during placebo treatment. Cisapride enhanced acid clearance but had no significant effect on the duration of acid exposure, the rate of reflux episodes, the pattern of lower oesophageal sphincter pressure associated with the reflux episodes, basal lower oesophageal sphincter pressure or oesophageal peristalsis. These findings do not suggest a major role for cisapride, at the dosage tested, for the control of troublesome postprandial gastro-oesophageal reflux.
Hollowav, Downton, Mitchell, and Dent Each study day was preceded by a three day oral loading with cisapride 10 mg tds or placebo. Between cisapride and placebo phases of the study there was a minimum washout period of three days. Gastric antisecretory agents were stopped a minimum of seven days before starting the study and any antacid use was suspended during study days.
MANOMETRIC AND OESOPHAGEAL PH RECORDINGS
Oesophageal manometry was done with a multilumen assembly that incorporated a sleeve sensor at its distal end." The catheter was positioned so that the sleeve straddled the lower oesophageal sphincter and thereby monitored sphincter pressure. A side hole 1 cm distal to the distal sleeve margin recorded intragastric pressure. Side holes at the level of the proximal sleeve margirn, and 4, 8, and 12 cm more proximally recorded motor activity in the oesophageal body. A side hole in the hypopharynx monitored swallowing. Each lumen was perfused with distilled water by a pneumohydraulic capilliary infusion pump. The gastric side hole and sleeve were perfused at 05 ml/min throughout the study. The side holes in the oesophageal body and pharynx were perfused at 0.5 ml/min during the assessment of water swallows. At other times these latter side holes were perfused at 0 13 ml/min in order to minimise the fluid load to the patient. This lower infusion rate was selected to yield reliable recognition of the occurrence of oesophageal body and pharyngeal contractions but to minimise any possible alteration of the patterns of oesophageal acid clearance or the rate of primary or secondary peristalsis by perfusion of the manometric assembly.
Oesophageal pH was monitored with a Radiometer (GK2801C) pH electrode positioned 5 cm above the proximal margin of the lower oesophageal sphincter. The electrode was calibrated in buffers of pH 4 and 7 before and after each study. Correction for any electrode drift (in all instances <0.4 pH units) was made on the assumption that the drift was linear during the study. Manometric and pH signals were processed and recorded on an eight channel Devices M19 chart recorder. Responses to water swallows were recorded at a paper speed of 4 mm/s, at all other times the paper speed was 80 mm/min. Plasma cisapride concentrations were measured at the laboratories of Janssen Pharmaceutica (Beerse, Belgium) using high performance liquid chromatography.
SrUUDY PROTOCOL Patients were studied after an overnight fast. The protocol for each study day is summarised in Fig. 1 . The patients remained recumbent on their right side except when swallowing the tablet and eating the 
Results
Technically satisfactory recordings were obtained on both study days in 14 of the 16 patients. In two patients, either the manometric or pH recordings (in one patient each, respectively) were technically unsatisfactory on one of the study days, and that part of the data could not be analysed.
Gastro-oesophageal reflux increased substantially after the meal on both study days. Duration of acid exposure was greatest during the first postprandial hour and decreased progressively thereafter. The rate of reflux episodes was similar for the cisapride and placebo treatments (Fig. 2) . Although median percent oesophageal acid exposure time with eisapride (11.5%) was less than that with placebo (18.5%), this difference was not significant (Fig. 3) . Acid clearance time after cisapride (84 s), however, was significantly less than that after placebo (126 s, p<005), (Fig. 4) . Basal lower oesophageal sphincter pressure decreased immediately after the meal and then returned to and, in some patients, exceeded preprandial levels after the first hour (Fig. 5) . Basal lower oesophageal sphincter pressure after cisapride, however, was not significantly different from that after placebo.
Analysis of the patterns of lower oesophageal sphincter motor function associated with the reflux episodes showed that almost 80% of episodes occurred during transient lower oesophageal sphincter relaxation (Fig. 6) . A small proportion (18%) occurred because of absent basal lower oesophageal sphincter pressure for at least 30 s before the onset of reflux. Occasionally (3%) reflux occurred during large pressure transients caused by straining or deep inspiration, almost invariably associated with low basal lower oesophageal sphincter pressure (<5 mmHg). Patients did not reflux exclusively via any one mechanism and the distribution of the three major mechanisms of reflux did not differ between cisapride and placebo treatments.
Parameters of peristalsis for the postprandial period are summarised in the Table. No The trough plasma cisapride level on the morning of the cisapride study was 48-1 (5-0) (SE) ng/ml. The plasma level rose significantly (p<0-01) after administration of cisapride (peak plasma level 75.9 (6.9) ng/ml) and remained raised for the remainder of the study period. Plasma cisapride concentrations were undetectable (<2 ng/ml) on the placebo study day.
Discussion
The stimulating effect of cisapride on basal lower oesophageal sphincter pressures has prompted the suggestion that it may have a role in the treatment of gastro-oesophageal reflux disease. In the present study we evaluated the effect of oral cisapride on postprandial oesophageal pH and motor function in patients with symptomatic reflux. Cisapride enhanced oesophageal acid clearance but had no significant effect on the duration of oesophageal acid exposure, the rate of reflux episodes, or oesophageal motility.
Our findings of a significant improvement in acid clearance supports those of previous studies,"' in which a reduction in the durations of individual reflux episodes and the longest reflux episodes has been a consistent finding. In two studies, the improvement in acid clearance was judged to be the principal factor underlying a reduction in oesophageal acid exposure.13 14 We have found no The failure of cisapride to decrease oesophageal acid exposure or the rate of reflux episodes contrasts with the findings of previous studies in children'3'`'""' in which consistent reductions in both these parameters have been observed. In adults, however, the effect on the rate of reflux episodes has been inconsistent.'4"2 There are several possible explanations. First, the dose used in our study, when adjusted for body weight was approximately half that used in children, although similar to that used in previous studies in adults. Pharmacological studies suggest that in adults at least a 20 mg oral dose is needed to increase lower oesophageal sphincter pressure significantly.`Second, the failure to achieve significance may have resulted from a type II error (B>0-8). Third, we studied our patients in the postprandial period. Other studies, in which cisapride reduced acid exposure and reflux rate, were done over much longer periods including during sleep. In only one study, in children, was the immediate two hour postprandial period analysed.'" In the remaining studies it is not possible to determine if the effect was evident for the postprandial or the fasting periods or both. The lower oesophageal sphincter appears to be less responsive to the motor stimulating effects of cisapride in the fed state when compared with the fasting state," possibly because excitatory neural influences that are acting on the lower oesophageal sphincter during the migrating motor complex cycle"'2 are less intense or absent. We did not observe any significant effect of cisapride on basal lower oesophageal sphincter pressure. This finding may be partly attributed to the route and timing of administration of the drug. At the dose tested, 10 6 In the present study we adopted a highly standardised approach, monitoring oesophageal motility and pH concurrently over the postprandial period using the same meal and a standardised body position. We believe that this approach offers distinct advantages over ambulatory pH monitoring. First, the experimental conditions can be more easily controlled, and standardised not only among subjects within studies, but also between studies in different centres. Second, recent studies have consistently found that the majority of reflux episodes occur during the day after meals,"7 and postprandial reflux appears to be more closely related to oesophagitis than is nocturnal reflux.2' Third, and most importantly, concurrent monitoring of oesophageal motility allows the assessment of the effects of these agents on the motor events underlying gastrooesophageal reflux.
In summary, cisapride 10 mg po, had no significant effect on postprandial gastro-oesophageal reflux or oesophageal motility although acid clearance was improved. These findings would suggest that cisapride, at least at the dosage tested, would be unlikely to be of major benefit in the control of troublesome postprandial gastro-oesophageal reflux. Recent studies, however, have shown that cisapride improves symptoms, and heals oesophagitis2"'9231 with an efficacy similar to that of ranitidine,' and is an effective adjunct to cimetidine in patients with severe oesophagitis.3 The mechanism(s) underlying these clinical effects are not completely clear but may involve a reduction in nocturnal acid exposure, an effect not tested for in the present study. 
